Related Experiment Video
Updated: May 6, 2026
05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
6.5K
Laparoscopic adjustable gastric banding and hypoglycemia
Sigrid Bairdain1, Mark Cleary, Chueh Lien
1Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Case Reports in Endocrinology
|November 8, 2013
Summary
Symptomatic hypoglycemia can occur after gastric banding surgery, not just Roux-en-Y gastric bypass. This study found three cases of hypoglycemia following laparoscopic adjustable gastric banding, suggesting it should be investigated regardless of the bariatric procedure.
Area of Science:
- Bariatric surgery outcomes
- Endocrinology
- Gastroenterology
Background:
- Obesity is a prevalent health concern requiring surgical intervention.
- Roux-en-Y gastric bypass (RYGB) is common but associated with side effects like hypoglycemia.
- Limited data exists on hypoglycemia after other bariatric procedures.
Purpose of the Study:
- To investigate the occurrence of symptomatic hypoglycemia after laparoscopic adjustable gastric banding (LAGB).
- To determine if hypoglycemia is exclusive to RYGB or can follow other bariatric operations.
Main Methods:
- Retrospective review of patients who underwent LAGB between 2008 and 2012.
- Identification and analysis of patients experiencing symptomatic hypoglycemia post-LAGB.
Main Results:
- Three patients developed symptomatic hypoglycemia following LAGB.
- Hypoglycemia occurred at a mean of 33 months post-surgery, with significant weight loss.
- None of the affected patients had pre-existing diabetes.
Conclusions:
- Symptomatic hypoglycemia is a potential complication following LAGB.
- Hypoglycemia should be investigated in patients experiencing symptoms, irrespective of the type of bariatric surgery performed.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:26Hypoglycemia
34
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
34
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
958
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K